A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory

Natalia Paez Arango, Lauren Brusco, Kenna R.Mills Shaw, Ken Chen, Agda Karina Eterovic, Vijaykumar Holla, Amber Johnson, Beate Litzenburger, Yekaterina B. Khotskaya, Nora Sanchez, Ann Bailey, Xiaofeng Zheng, Chacha Horombe, Scott Kopetz, Carol J. Farhangfar, Mark Routbort, Russell Broaddus, Elmer V. Bernstam, John Mendelsohn, Gordon MillsFunda Meric-Bernstam

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility of performing broad genomic testing in the research laboratory for discovery, and the utility of giving treating physicians access to research data, with the option of validating actionable alterations in the CLIA environment. Experimental design: 1200 patients with advanced cancer underwent characterization of their tumors with high depth hybrid capture sequencing of 201 genes in the research setting. Tumors were also tested in the CLIA laboratory, with a standardized hotspot mutation analysis on an 11, 46 or 50 gene platform. Results: 527 patients (44%) had at least one likely somatic mutation detected in an actionable gene using hotspot testing. With the 201 gene panel, 945 patients (79%) had at least one alteration in a potentially actionable gene that was undetected with the more limited CLIA panel testing. Sixty-four genomic alterations identified on the research panel were subsequently tested using an orthogonal CLIA assay. Of 16 mutations tested in the CLIA environment, 12 (75%) were confirmed. Twenty-five (52%) of 48 copy number alterations were confirmed. Nine (26.5%) of 34 patients with confirmed results received genotype-matched therapy. Seven of these patients were enrolled onto genotype-matched targeted therapy trials. Conclusion: Expanded cancer gene sequencing identifies more actionable genomic alterations. The option of CLIA validating research results can provide alternative targets for personalized cancer therapy.

Original languageEnglish (US)
Pages (from-to)41806-41814
Number of pages9
JournalOncotarget
Volume8
Issue number26
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Feasibility Studies
Research
Genes
Mutation
Neoplasms
Genotype
Neoplasm Genes
Research Design
Therapeutics
Physicians

Keywords

  • CLIA
  • Clinical trial
  • Genomics
  • Precision medicine
  • Somatic mutation

ASJC Scopus subject areas

  • Oncology

Cite this

Arango, N. P., Brusco, L., Shaw, K. R. M., Chen, K., Eterovic, A. K., Holla, V., ... Meric-Bernstam, F. (2017). A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget, 8(26), 41806-41814. https://doi.org/10.18632/oncotarget.16018

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. / Arango, Natalia Paez; Brusco, Lauren; Shaw, Kenna R.Mills; Chen, Ken; Eterovic, Agda Karina; Holla, Vijaykumar; Johnson, Amber; Litzenburger, Beate; Khotskaya, Yekaterina B.; Sanchez, Nora; Bailey, Ann; Zheng, Xiaofeng; Horombe, Chacha; Kopetz, Scott; Farhangfar, Carol J.; Routbort, Mark; Broaddus, Russell; Bernstam, Elmer V.; Mendelsohn, John; Mills, Gordon; Meric-Bernstam, Funda.

In: Oncotarget, Vol. 8, No. 26, 01.01.2017, p. 41806-41814.

Research output: Contribution to journalArticle

Arango, NP, Brusco, L, Shaw, KRM, Chen, K, Eterovic, AK, Holla, V, Johnson, A, Litzenburger, B, Khotskaya, YB, Sanchez, N, Bailey, A, Zheng, X, Horombe, C, Kopetz, S, Farhangfar, CJ, Routbort, M, Broaddus, R, Bernstam, EV, Mendelsohn, J, Mills, G & Meric-Bernstam, F 2017, 'A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory', Oncotarget, vol. 8, no. 26, pp. 41806-41814. https://doi.org/10.18632/oncotarget.16018
Arango, Natalia Paez ; Brusco, Lauren ; Shaw, Kenna R.Mills ; Chen, Ken ; Eterovic, Agda Karina ; Holla, Vijaykumar ; Johnson, Amber ; Litzenburger, Beate ; Khotskaya, Yekaterina B. ; Sanchez, Nora ; Bailey, Ann ; Zheng, Xiaofeng ; Horombe, Chacha ; Kopetz, Scott ; Farhangfar, Carol J. ; Routbort, Mark ; Broaddus, Russell ; Bernstam, Elmer V. ; Mendelsohn, John ; Mills, Gordon ; Meric-Bernstam, Funda. / A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. In: Oncotarget. 2017 ; Vol. 8, No. 26. pp. 41806-41814.
@article{6c4019412d3747d789804c63565f961e,
title = "A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory",
abstract = "Purpose: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility of performing broad genomic testing in the research laboratory for discovery, and the utility of giving treating physicians access to research data, with the option of validating actionable alterations in the CLIA environment. Experimental design: 1200 patients with advanced cancer underwent characterization of their tumors with high depth hybrid capture sequencing of 201 genes in the research setting. Tumors were also tested in the CLIA laboratory, with a standardized hotspot mutation analysis on an 11, 46 or 50 gene platform. Results: 527 patients (44{\%}) had at least one likely somatic mutation detected in an actionable gene using hotspot testing. With the 201 gene panel, 945 patients (79{\%}) had at least one alteration in a potentially actionable gene that was undetected with the more limited CLIA panel testing. Sixty-four genomic alterations identified on the research panel were subsequently tested using an orthogonal CLIA assay. Of 16 mutations tested in the CLIA environment, 12 (75{\%}) were confirmed. Twenty-five (52{\%}) of 48 copy number alterations were confirmed. Nine (26.5{\%}) of 34 patients with confirmed results received genotype-matched therapy. Seven of these patients were enrolled onto genotype-matched targeted therapy trials. Conclusion: Expanded cancer gene sequencing identifies more actionable genomic alterations. The option of CLIA validating research results can provide alternative targets for personalized cancer therapy.",
keywords = "CLIA, Clinical trial, Genomics, Precision medicine, Somatic mutation",
author = "Arango, {Natalia Paez} and Lauren Brusco and Shaw, {Kenna R.Mills} and Ken Chen and Eterovic, {Agda Karina} and Vijaykumar Holla and Amber Johnson and Beate Litzenburger and Khotskaya, {Yekaterina B.} and Nora Sanchez and Ann Bailey and Xiaofeng Zheng and Chacha Horombe and Scott Kopetz and Farhangfar, {Carol J.} and Mark Routbort and Russell Broaddus and Bernstam, {Elmer V.} and John Mendelsohn and Gordon Mills and Funda Meric-Bernstam",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16018",
language = "English (US)",
volume = "8",
pages = "41806--41814",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory

AU - Arango, Natalia Paez

AU - Brusco, Lauren

AU - Shaw, Kenna R.Mills

AU - Chen, Ken

AU - Eterovic, Agda Karina

AU - Holla, Vijaykumar

AU - Johnson, Amber

AU - Litzenburger, Beate

AU - Khotskaya, Yekaterina B.

AU - Sanchez, Nora

AU - Bailey, Ann

AU - Zheng, Xiaofeng

AU - Horombe, Chacha

AU - Kopetz, Scott

AU - Farhangfar, Carol J.

AU - Routbort, Mark

AU - Broaddus, Russell

AU - Bernstam, Elmer V.

AU - Mendelsohn, John

AU - Mills, Gordon

AU - Meric-Bernstam, Funda

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility of performing broad genomic testing in the research laboratory for discovery, and the utility of giving treating physicians access to research data, with the option of validating actionable alterations in the CLIA environment. Experimental design: 1200 patients with advanced cancer underwent characterization of their tumors with high depth hybrid capture sequencing of 201 genes in the research setting. Tumors were also tested in the CLIA laboratory, with a standardized hotspot mutation analysis on an 11, 46 or 50 gene platform. Results: 527 patients (44%) had at least one likely somatic mutation detected in an actionable gene using hotspot testing. With the 201 gene panel, 945 patients (79%) had at least one alteration in a potentially actionable gene that was undetected with the more limited CLIA panel testing. Sixty-four genomic alterations identified on the research panel were subsequently tested using an orthogonal CLIA assay. Of 16 mutations tested in the CLIA environment, 12 (75%) were confirmed. Twenty-five (52%) of 48 copy number alterations were confirmed. Nine (26.5%) of 34 patients with confirmed results received genotype-matched therapy. Seven of these patients were enrolled onto genotype-matched targeted therapy trials. Conclusion: Expanded cancer gene sequencing identifies more actionable genomic alterations. The option of CLIA validating research results can provide alternative targets for personalized cancer therapy.

AB - Purpose: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility of performing broad genomic testing in the research laboratory for discovery, and the utility of giving treating physicians access to research data, with the option of validating actionable alterations in the CLIA environment. Experimental design: 1200 patients with advanced cancer underwent characterization of their tumors with high depth hybrid capture sequencing of 201 genes in the research setting. Tumors were also tested in the CLIA laboratory, with a standardized hotspot mutation analysis on an 11, 46 or 50 gene platform. Results: 527 patients (44%) had at least one likely somatic mutation detected in an actionable gene using hotspot testing. With the 201 gene panel, 945 patients (79%) had at least one alteration in a potentially actionable gene that was undetected with the more limited CLIA panel testing. Sixty-four genomic alterations identified on the research panel were subsequently tested using an orthogonal CLIA assay. Of 16 mutations tested in the CLIA environment, 12 (75%) were confirmed. Twenty-five (52%) of 48 copy number alterations were confirmed. Nine (26.5%) of 34 patients with confirmed results received genotype-matched therapy. Seven of these patients were enrolled onto genotype-matched targeted therapy trials. Conclusion: Expanded cancer gene sequencing identifies more actionable genomic alterations. The option of CLIA validating research results can provide alternative targets for personalized cancer therapy.

KW - CLIA

KW - Clinical trial

KW - Genomics

KW - Precision medicine

KW - Somatic mutation

UR - http://www.scopus.com/inward/record.url?scp=85021296288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021296288&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16018

DO - 10.18632/oncotarget.16018

M3 - Article

AN - SCOPUS:85021296288

VL - 8

SP - 41806

EP - 41814

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -